In a bold stride for the biotech industry, Dr. Erin E. Mauney of Tufts University and Massachusetts General Hospital is spearheading an unprecedented clinical trial which employs psilocybin, a naturally occurring psychedelic compound, in the treatment of intractable irritable bowel syndrome (IBS). This groundbreaking research, representing a pioneering shift in gastroenterology, offers a beacon of […]
Tag: psilocybin
Bill Retry for Psilocybin as Veteran PTSD Treatment
In the heartland of America, the Show-Me state of Missouri is the latest battleground in the push for the therapeutic use of psilocybin, a psychedelic compound found in certain mushrooms. Despite the initial legislative setback in the Missouri House, proponents of a bill that endorses psilocybin as a treatment for post-traumatic stress disorder (PTSD) in […]
Potential Breakthrough Moment: Psychedelics in Clinical Trials
The psychedelic revolution is no longer on the horizon; it is here. A confluence of regulatory strides, clinical advancements, and increasing acceptance of these once-taboo substances signals a pivotal transformation in mental healthcare. As the field of biotechnology leaves no stone unturned in the quest for innovative treatments for mental health disorders, psychedelics have emerged […]